NCT00192153

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Adults 18 to 59 Years and Healthy Adults,60 Years/Older

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (planned)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to develop assays for application in investigating potential immunological correlates of protection and/or establishing assays to measure vaccine take.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	CAIV-T or TIV

Timeline

• Start date: 2001-07-01
• Completion: 2001-10-01
• First posted: 2005-09-19
• Last updated: 2021-09-13

Locations

2 sites across 1 country: United States